DOCSLIB.ORG

Epidemiology Student Handbook 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Epidemiology Student Handbook 2020 JOHNS HOPKINS BLOOMBERG SCHOOL of PUBLIC HEALTH Epidemiology Academic Year 2020-21 ACADEMIC HANDBOOK @JohnsHopkinsEPI johnshopkins_epi 1 TABLE OF CONTENTS I. WELCOME FROM THE CHAIR II. DEPARTMENT MISSION AND GOALS Ill. DEPARTMENT ORGANIZATION AND DIRECTORY a. Chair and Deputy Chairs b. Central Administration c. Academic Core, Student Funding Manager, and Communications Associate d. Epidemiology Tracks and Track Directors DEGREE PROGRAMS IN EPIDEMIOLOGY I. DOCTORAL PROGRAM a. Doctoral Program Co-Directors b. Doctoral Welcome Letter c. Doctor of Philosophy Degree Program d. Academic Advising e. Policies Related to PhD Mentoring II. DOCTORAL REQUIREMENTS a. Residency b. Track-Specific Activities c. Quarterly Doctoral Meetings d. Aca~e~ic & Research Ethics (and Avoiding Plag1ar1sm) Course Requirement 2 e. Responsible Conduct of Research Course Requirement f. Academic Coursework g. Core Coursework i. Council on Education for Public Health Requirements ii. Recommendations for Special Studies versus Thesis Research h. Doctoral Coursework by Track: i. Cancer Epidemiology ii. Cardiovascular and Clinical Epidemiology iii. Clinical Trials and Evidence Synthesis iv. Environmental Epidemiology v. Epidemiology of Aging vi. General Epidemiology and Methodology vii. Genetic Epidemiology viii. Infectious Disease Epidemiology i. Department Comprehensive Examination j. Comprehensive Examination Grading Policy k. Comprehensive Examination Retake Policy I. Doctoral Teaching Assistant Curriculum Requirements i. Purpose of the Doctoral TA Curriculum ii. Components of the Doctoral TA Curriculum iii. Documentation of Teaching Experience for a Resume or Curriculum Vitae iv. Waivers v. Compensated TA Positions vi. Benefits of Teaching (from former TAs) vii. Timeline and Steps for Completion of the TA Curriculum viii. Instructor Feedback Form ix. Guide to Documentation for a Resume or Curriculum Vitae 3 m. Other Teaching Opportunities i. Department of Epidemiology Named Teaching Assistantships ii. University Named Teaching Fellowship n. Thesis Advisory Committee o. Dissertation Research Proposal p. Doctoral Research Proposal Seminar q. Departmental Oral Examination r. Preliminary Oral Examination s. Primary Data Collection Requirement t. Doctoral Dissertation u. Final Defense Seminar v. Final Oral Examination Ill. DOCTORAL FLOWCHART AND GRADUATION DEADLINES a. Flowchart for the Doctoral Program IV. [M]~~Tf~~9~ [g)~(Q)@~~[M]~«rMlG=D~ @ITDcol ~©rMl~ a. IB01lc&1~fr@[fg~[g)ffi@jffi[[ffi [D)nm©il@rn b. IB01lc&1~il@rrg~MM@~©@mru@ rL@ilil@rr c. IB01Jc&1~il®rr@~ [}={J@c&1rnrru ~@ □ ®ITTI@® c&JITTI@IB01Jc&1~il®rr @~~@ □ ®ITTI@® [g)ffi@J ffi [[ill~ d. &@c&J@@mruo©&cdlwn~ □ ITTI@J V. rMl~~Tf~~9~ ~~@(U]~~~rMl~~Tf~ a. ~@~ n@@ITTI©W b. 1fm©fl& 0 ~[p)@©om@&@ilnwoil n@~ c. @lUJc&Jflli@f'f~W IB01lc&1~fr@[fg~IB0\J@@il □ ITTI@j~ 4 d. ;%@@1cctJ®oo □ © ~ ~®~®@rerru~frrruo@~ «@rrncctJ &w@ occtJ □ rrn® [F) ~ @~D@rr □ ~oo» CC@Mrr~@~@CoJM □ moo@rrn fr e. ~@~[p)@fill~o[ls)~@CC@rrncctJM©fr @ff~@~@c&}[f© [ill(C;@[U)ffi@ ~®CoJ[UJ□ rn oo®rrn fr f. ;%@c&)cctJ@oon@CC@Mrr~@m@rrrk< g. CC@mCC@Mrn@m@rrrk< i. CG@[UJITTJ@O~@[DJ[§'.©J[UJ@®U □ @rru ~@IT'[g}[UJ[b)~n@ fHJ@®rnfrn ~@(oJ[UJOff®OO®ITTJl® ii. ~®@@oooo@rru@®U □ @rru~ ~@rr~!JS)®@ □ ®~ ~fr[UJ@ □ ®~ W®IT'~[UJ~Jffrn @~n~ ~®~®®IT'@frn h. IBval@~fr@rf9~ CC@Mrf~@m@rrrk<[ls)W1f m@rk<~ i. CG®rru@@ rr l§'. !JS) n@@oo o@ ~ @®W ii. CG®MO@\Vl®~@[UJ~®IT'®ITTJ©CG~nrruo@®~ l§'.[p)O©®OOO@~@®W iii. ce~ orru □ @®~ Jfrr □ ®~~ ®rru@l§'.ws©l®rru@® ~wrruUfrn®~ □~ iv. l§'.rruw nffi ITTJoo@ rrufr® ~ l§'.!JS) n@®oo □ @ ~ @®W v. l§'.IJS)o@@oon@~@®W@~t%® □ ITTJ® vi. ®@rru@ra~l§'.IJS)n@@oon@~@®W ®rru@fMJ@ Ufrn@@@~@@W vii. @@rru@Un@ l§'.IJS)o@@oon@~@@W viii. ~rru~@@U □ @[UJ~ [o)n~@®~@l§'.IJS)o@@oon@~@@W i . [D)@[p)@ rrfrrIDTI@ rrnfrCC@rIDTI [p2m [ru@rrn ~ OW@ ~M@ [ID)) n fill@fr □ @fill j . CC@oo[r62rr® rru ®rrn ~ ow® ~21@ ooo rrn@fr □ @rm @mcctJ orm® [§)@ ~ o@W k. CC@oo[p)m[ru@rrn~nw@~2Z@rIDTIDfill@fr □ @rrn ~®fr@rk<®[F)@~ncy I• 1f®@© [run rm® ;%~~ n~fr@ rmfr ~@©@rIDTIoo@rrncctJ @fr o @rrn~ i. Jf®®@frn □ rru® &~~ □ ~U®rruu Jfrr® □ rru □ rru®~ ®rru@~®~@[U)re®~ ii. @[UJ □ @® fr@[o)@@[UJOO@rruU®U □ @rru ~@rr® ~@~[UJOO@@rr CG[UJIT'IT' □ @[UJ~[UJOO '.MDU®@ m. IBval@~fr@[f9~ '[[ru@~n~«IBvaJrcn~» n. IBval@~fr@[f9~ '[[ru@~n~ «~@IBvaJ» o. IBval@~fr@rr9~ 1f[ru@~n~ ~2Z[p2@©fr@fr □ @rrn~ p. IBval@~fr@[f9~ [g)@~fr@[f~@~~ □ @fill 5 VI. [M]ffi\~1f~ ~ 9 ~ re[l©~ce ro1&\~1f &\[Kl][D) @ ~ffi\[D) Mffi\ 1f~(O)[KJ] [D)~ffi\[D)[l~[KJ]~~(8)11 [D) ~@~~~ a. re~@%'11© rm @l [ill~ ff@[f' fr[ru@[iMjJ @l~il@rt' 9 ~ [°g)ffi® [f'@lm:ru~ i. rMl[l=(J ~ [§)IT'@® rn oo ~@IT'~u M@® [I})*~ w rm@® [I})IT'@~ ~ □ [I})~® ~ ii. [M][l=(J~[D)@®@~n[I})@~ ~@IT' @rn@M®U □ @[I}) iii. ~~[Ml [§)Cf'@®rnITTID~IT' ~UM@@[l})fr~w[n)@ @[l})IT'@~~□ [I}) ~@[P) iv. ~~[Ml [D)@®@~ □ [I})@~ ~@IT'CCSJIT'®@M®U □ @[I}) v11. f85&\ce ro1~ [l(O) ~ ffi\[Kl][D) rMlffi\~1f ~ ~ 9 ~ ce©rMl f85 ~[Kl]~ [D) [g)~(O)@ ~&\[Ml ~ [g)ffi\§[M]ro1~~ a. L@ffeJ[MjJ[}=[J~Tf □ m:ru@~ □ rru@~ = (C;@m:rn[i6)ffi~~@@@l[D)@ ~@®M~@lrt' b. re~@m©rru©lrruff@[f' ilrru@L@ffeJuMil[}=[J~ cc;@m:ru@orru@col [@)[f'@®ram:ru c. L@NuMil[}=[J~ [o)@@l@~ orru@~ ff@[f' @racolM ©lil □ @rru VIII. NON-DEGREE TRAINING a. Postdoctoral Fellows (PDF) i. PDE Program Co-Directors ii. Career Development Resources iii. Helpful PDE Links b. Certificate Programs c. Graduate Summer Institute of Epidemiology and Biostatistics IX. 6 X. &~&[D) ~ rMJ~~[F)©[l ~~~~~ &[M[D) [F)~©~ ~ [D)[UJ~~ ~ a. &©cruCQ]@mruo©lEfr[o)o ©~ lP@~ □ ©Wl~frMCQ]@ITDfr ce@ITDCQ]M©fr b. (e©)~@fn)CQ]©)[f@frlE[p)o □mnCQ]@ rEW@ITDfr~ c. (e[ill©)fn)®@@fr &CQ]wn~@[f d. (eofrcIDfrD@ITD~cruITDCQ] ~@ff@fflITD©@~ e. ce@[UJ[f~@\½McIDOW@[f~ @fr[D)@®IT'@@#lPm®ramru ~@(ClJ[UJ O[f@[illi@fn)fr~ f. [D)@[p)cIDIT'frmru@ITDfrcID~~@WO@W,Z@ff ffe\©©)CQ]@mru □ © r@ffi@j[f@~~ g. rE~@©frffiITDO© ce@mrumruMITDO©crufrD@ITD h. ~©[o)@@~mnCQ]@~@W O@W§@fr ffe\©©)CQ]@mru □ © r@ffi@jffl~~ i. R..,@cIDW@@fr&@~@ITD©@ j. ~®® □ ~frrafr □ @ITD k. ~®® □ ~frrafr □ @ITD ff@rrlPcID~~llecID □ ~ (Q)[p)fr □ @ITD 1. 1f □ mru® ~frcIDfrM~ce[o)cIDITD®® «re[UJ~~ □fromru® fr@ lPcIDru □fromru®» m. 1frEcIDITD~ff@rr~ n. JLIT'cIDW@~ o. ce~®rEW&©fr XI. FINANCIAL INFORMATION a. Master's Student Financial Support i. Master's Tuition Scholarship ii. Department Endowments (Continuing Master's Students) iii. Other Departmental Support Funds (Master's Students) 7 b. Doctoral Student Financial Support i. NIH NRSA 132 Training Grants (Pre- and Postdoctoral Fellowships) ii. NIH F-Level Individual Predoctoral National Research Service Awards (NRSAs) iii. Other Training Awards (Non-NIH) iv. Department Endowments (Incoming Doctoral Students) v. Department Endowment (Continuing Doctoral Students) vi. Other Departmental Support Funds c. Schoolwide Funding Opportunities d. Student Grant Application Assistance e. Student Account Information f. Helpful Contact Information XII. ~Tf(lJJ [D) [§'. [K1]Tf [l ~[e [§'. ffi\[K1] [D)[g) ~(CS) [e [§'.~~~(CS) [K1lffi\ [L (0)~@& [K1]~a:&Tf ~ (0) [K1] ~ a. [D)nw@rr~nfrw@ITTI@ ~ITTI© ~M~D@ITTI~~[p)D@@fIDDD@~@~W [D)®[p)@rrufIDD@rrufr» i. ~ITD@~[UJ~ □ @ITD 9 [D)nsvz@IT'~ □ fcw 9 l§:(9JM □ fcw 9 ffe\ITDfr □ 0rfil®@ □ ~OO ~ ~@ □ @ITD@@ «l§:[P) □ ~[D)[§:f/4\~»\\W@IT'~~IT'@[UJ[P) b. ~[p)D@@fIDDD@~@~W~frM@@ITTifr (Q)ff®@ITTID?2@fro@rru c. ~[p) □ @@fIDD □ @~@~W ~frM@@rrufr~@@fIDD d. [§)m~@~~ □ @ITTI@~ (Q)ff®@ITTIDZ2@fr □ @rru~ i. ~@@ □ ®few ~@IT'l§:[P) □ @®mro □ @~@~ □ @ rfil®~®®IT'@rru«~l§:rfil» ii. &mro@IT' □ @®ITD CE;@~~®~®@~ l§:[P) □ @®mro □ @~@~w iii. &mro®IT' □ @®ITD [§)[UJfb2~ □ @ rKJ@®rnrru&~~@@ □ ®fr □ @ITD e. ~©n@rrufrom@[@)[UJ@ ~o©@frD@ITTI~ i. //4\00@IT' □ @®ITD JJ@MIT'ITD®~@~ l§:[P) □ @@OO □ @~@~W «&J [§:» ii. l§:[P) □ @@mron@~@~n@ rfil@wn@w~ f. Gsl@@~fr[ru@ITTI@ ~~~ □ ~@DITTI~ 8 g. ~©[ill@@~\'070 @@ ~@~@ [UJ [©@~ i. ffei©®@@oo □ © (E;®~@rrn@®IT' ii. (Q;@)[f'@@[f'~@NO©@~ iii. (Q;@[UJ[f'~@(Q;®il®~@@ iv. (Q;@[UJIT'~@[g}~[UJ~ v. [D)o~®[ls)o~ □ itw ~[UJ[p)[p)@ru~®N □ ©®~ vi. w®©M~ftw[D)nrt'@©il@IT:W vii. le o rrn®rrn© □ ®~ '®in@ viii. [l=/J@[p)~ □ rrn~ [MJ@©l □ ©®~ ~@@~ (E;@rrnil@IT' ix. ~UM@@rrnU~rrn~@IT'oo®U □ @rrn ~w~U@oo «~~~» x. ~®©@M~ ®rrn©l~®@ □ ~UIT'®il □ @rrn xi. ~(O)[UJ~(E;[§'.«~UM@@rrnU (Q)Milrf'@®©[ru ~@~@[UJ[f'©@ (Q;@rrnU@~ xii. ~UM@@rrnU!&i©©@[UJmJil @)[OJ@ ~[UJ~ □ rrn@~~ ~@NO©@~ xiii. ~UM@@rrnUffei~~ n~U®rrn©@[g)ro@moo «JJ[)=(J~ffei[g)» xiv. ~UM@@rrnUffei~~@oo[ls)~W xv. fl n[ls)[f'® IT' □ @~ xvi. ~UM@@rrnU[l=/J@® ~U[ru~ mJ~MIT'®mJ©@ h. [D)nsvz@rr~nfrw~ITTI@ ~ITTI© ~M~D@ITTI~~@@om@ITTI~~ ~@~@Mff©@~» i. 1fo~~@~ 2A All policies and procedure are subject to change. The Department of Epidemiology reserves the right to amend or change policies and procedures at any time. Every reasonable effort will be made to notify students and fellows of any changes. 9 WELCOME FROM THE CHAIRS II,...... ,. JOHNS HOPKINS BLOOMBERG CHOOL of PUBLIC HEALTH August 2020 Welcome to the Department of Epidemiology. You are joining the Department whose first chair (Wade Hampton Frost) developed foundational epidemiologic methods at the time of the 1918-19 flu pandemic that devastated the US and the rest of the world. We find ourselves in 2020, facing another devastating pandemic- SARS-CoV-2/COVID-19.
Load more

Recommended publications
  • The Magic of Randomization Versus the Myth of Real-World Evidence
    The new england journal of medicine Sounding Board The Magic of Randomization versus the Myth of Real-World Evidence Rory Collins, F.R.S., Louise Bowman, M.D., F.R.C.P., Martin Landray, Ph.D., F.R.C.P., and Richard Peto, F.R.S. Nonrandomized observational analyses of large safety and efficacy because the potential biases electronic patient databases are being promoted with respect to both can be appreciable. For ex- as an alternative to randomized clinical trials as ample, the treatment that is being assessed may a source of “real-world evidence” about the effi- well have been provided more or less often to cacy and safety of new and existing treatments.1-3 patients who had an increased or decreased risk For drugs or procedures that are already being of various health outcomes. Indeed, that is what used widely, such observational studies may in- would be expected in medical practice, since both volve exposure of large numbers of patients. the severity of the disease being treated and the Consequently, they have the potential to detect presence of other conditions may well affect the rare adverse effects that cannot plausibly be at- choice of treatment (often in ways that cannot be tributed to bias, generally because the relative reliably quantified). Even when associations of risk is large (e.g., Reye’s syndrome associated various health outcomes with a particular treat- with the use of aspirin, or rhabdomyolysis as- ment remain statistically significant after adjust- sociated with the use of statin therapy).4 Non- ment for all the known differences between pa- randomized clinical observation may also suf- tients who received it and those who did not fice to detect large beneficial effects when good receive it, these adjusted associations may still outcomes would not otherwise be expected (e.g., reflect residual confounding because of differ- control of diabetic ketoacidosis with insulin treat- ences in factors that were assessed only incom- ment, or the rapid shrinking of tumors with pletely or not at all (and therefore could not be chemotherapy).
    [Show full text]
  • (Meta-Analyses of Observational Studies in Epidemiology) Checklist
    MOOSE (Meta-analyses Of Observational Studies in Epidemiology) Checklist A reporting checklist for Authors, Editors, and Reviewers of Meta-analyses of Observational Studies. You must report the page number in your manuscript where you consider each of the items listed in this checklist. If you have not included this information, either revise your manuscript accordingly before submitting or note N/A. Reporting Criteria Reported (Yes/No) Reported on Page No. Reporting of Background Problem definition Hypothesis statement Description of Study Outcome(s) Type of exposure or intervention used Type of study design used Study population Reporting of Search Strategy Qualifications of searchers (eg, librarians and investigators) Search strategy, including time period included in the synthesis and keywords Effort to include all available studies, including contact with authors Databases and registries searched Search software used, name and version, including special features used (eg, explosion) Use of hand searching (eg, reference lists of obtained articles) List of citations located and those excluded, including justification Method for addressing articles published in languages other than English Method of handling abstracts and unpublished studies Description of any contact with authors Reporting of Methods Description of relevance or appropriateness of studies assembled for assessing the hypothesis to be tested Rationale for the selection and coding of data (eg, sound clinical principles or convenience) Documentation of how data were classified
    [Show full text]
  • Quasi-Experimental Studies in the Fields of Infection Control and Antibiotic Resistance, Ten Years Later: a Systematic Review
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Infect Control Manuscript Author Hosp Epidemiol Manuscript Author . Author manuscript; available in PMC 2019 November 12. Published in final edited form as: Infect Control Hosp Epidemiol. 2018 February ; 39(2): 170–176. doi:10.1017/ice.2017.296. Quasi-experimental Studies in the Fields of Infection Control and Antibiotic Resistance, Ten Years Later: A Systematic Review Rotana Alsaggaf, MS, Lyndsay M. O’Hara, PhD, MPH, Kristen A. Stafford, PhD, MPH, Surbhi Leekha, MBBS, MPH, Anthony D. Harris, MD, MPH, CDC Prevention Epicenters Program Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland. Abstract OBJECTIVE.—A systematic review of quasi-experimental studies in the field of infectious diseases was published in 2005. The aim of this study was to assess improvements in the design and reporting of quasi-experiments 10 years after the initial review. We also aimed to report the statistical methods used to analyze quasi-experimental data. DESIGN.—Systematic review of articles published from January 1, 2013, to December 31, 2014, in 4 major infectious disease journals. METHODS.—Quasi-experimental studies focused on infection control and antibiotic resistance were identified and classified based on 4 criteria: (1) type of quasi-experimental design used, (2) justification of the use of the design, (3) use of correct nomenclature to describe the design, and (4) statistical methods used. RESULTS.—Of 2,600 articles, 173 (7%) featured a quasi-experimental design, compared to 73 of 2,320 articles (3%) in the previous review (P<.01). Moreover, 21 articles (12%) utilized a study design with a control group; 6 (3.5%) justified the use of a quasi-experimental design; and 68 (39%) identified their design using the correct nomenclature.
    [Show full text]
  • Epidemiology and Biostatistics (EPBI) 1
    Epidemiology and Biostatistics (EPBI) 1 Epidemiology and Biostatistics (EPBI) Courses EPBI 2219. Biostatistics and Public Health. 3 Credit Hours. This course is designed to provide students with a solid background in applied biostatistics in the field of public health. Specifically, the course includes an introduction to the application of biostatistics and a discussion of key statistical tests. Appropriate techniques to measure the extent of disease, the development of disease, and comparisons between groups in terms of the extent and development of disease are discussed. Techniques for summarizing data collected in samples are presented along with limited discussion of probability theory. Procedures for estimation and hypothesis testing are presented for means, for proportions, and for comparisons of means and proportions in two or more groups. Multivariable statistical methods are introduced but not covered extensively in this undergraduate course. Public Health majors, minors or students studying in the Public Health concentration must complete this course with a C or better. Level Registration Restrictions: May not be enrolled in one of the following Levels: Graduate. Repeatability: This course may not be repeated for additional credits. EPBI 2301. Public Health without Borders. 3 Credit Hours. Public Health without Borders is a course that will introduce you to the world of disease detectives to solve public health challenges in glocal (i.e., global and local) communities. You will learn about conducting disease investigations to support public health actions relevant to affected populations. You will discover what it takes to become a field epidemiologist through hands-on activities focused on promoting health and preventing disease in diverse populations across the globe.
    [Show full text]
  • Guidelines for Reporting Meta-Epidemiological Methodology Research
    EBM Primer Evid Based Med: first published as 10.1136/ebmed-2017-110713 on 12 July 2017. Downloaded from Guidelines for reporting meta-epidemiological methodology research Mohammad Hassan Murad, Zhen Wang 10.1136/ebmed-2017-110713 Abstract The goal is generally broad but often focuses on exam- Published research should be reported to evidence users ining the impact of certain characteristics of clinical studies on the observed effect, describing the distribu- Evidence-Based Practice with clarity and transparency that facilitate optimal tion of research evidence in a specific setting, exam- Center, Mayo Clinic, Rochester, appraisal and use of evidence and allow replication Minnesota, USA by other researchers. Guidelines for such reporting ining heterogeneity and exploring its causes, identifying are available for several types of studies but not for and describing plausible biases and providing empirical meta-epidemiological methodology studies. Meta- evidence for hypothesised associations. Unlike classic Correspondence to: epidemiological studies adopt a systematic review epidemiology, the unit of analysis for meta-epidemio- Dr Mohammad Hassan Murad, or meta-analysis approach to examine the impact logical studies is a study, not a patient. The outcomes Evidence-based Practice Center, of certain characteristics of clinical studies on the of meta-epidemiological studies are usually not clinical Mayo Clinic, 200 First Street 6–8 observed effect and provide empirical evidence for outcomes. SW, Rochester, MN 55905, USA; hypothesised associations. The unit of analysis in meta- In this guide, we adapt the items used in the PRISMA murad. mohammad@ mayo. edu 9 epidemiological studies is a study, not a patient. The statement for reporting systematic reviews and outcomes of meta-epidemiological studies are usually meta-analysis to fit the setting of meta- epidemiological not clinical outcomes.
    [Show full text]
  • Simple Linear Regression: Straight Line Regression Between an Outcome Variable (Y ) and a Single Explanatory Or Predictor Variable (X)
    1 Introduction to Regression \Regression" is a generic term for statistical methods that attempt to fit a model to data, in order to quantify the relationship between the dependent (outcome) variable and the predictor (independent) variable(s). Assuming it fits the data reasonable well, the estimated model may then be used either to merely describe the relationship between the two groups of variables (explanatory), or to predict new values (prediction). There are many types of regression models, here are a few most common to epidemiology: Simple Linear Regression: Straight line regression between an outcome variable (Y ) and a single explanatory or predictor variable (X). E(Y ) = α + β × X Multiple Linear Regression: Same as Simple Linear Regression, but now with possibly multiple explanatory or predictor variables. E(Y ) = α + β1 × X1 + β2 × X2 + β3 × X3 + ::: A special case is polynomial regression. 2 3 E(Y ) = α + β1 × X + β2 × X + β3 × X + ::: Generalized Linear Model: Same as Multiple Linear Regression, but with a possibly transformed Y variable. This introduces considerable flexibil- ity, as non-linear and non-normal situations can be easily handled. G(E(Y )) = α + β1 × X1 + β2 × X2 + β3 × X3 + ::: In general, the transformation function G(Y ) can take any form, but a few forms are especially common: • Taking G(Y ) = logit(Y ) describes a logistic regression model: E(Y ) log( ) = α + β × X + β × X + β × X + ::: 1 − E(Y ) 1 1 2 2 3 3 2 • Taking G(Y ) = log(Y ) is also very common, leading to Poisson regression for count data, and other so called \log-linear" models.
    [Show full text]
  • A Systematic Review of Quasi-Experimental Study Designs in the Fields of Infection Control and Antibiotic Resistance
    INVITED ARTICLE ANTIMICROBIAL RESISTANCE George M. Eliopoulos, Section Editor A Systematic Review of Quasi-Experimental Study Designs in the Fields of Infection Control and Antibiotic Resistance Anthony D. Harris,1,2 Ebbing Lautenbach,3,4 and Eli Perencevich1,2 1 2 Division of Health Care Outcomes Research, Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, and Veterans Downloaded from https://academic.oup.com/cid/article/41/1/77/325424 by guest on 24 September 2021 Affairs Maryland Health Care System, Baltimore, Maryland; and 3Division of Infectious Diseases, Department of Medicine, and 4Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania We performed a systematic review of articles published during a 2-year period in 4 journals in the field of infectious diseases to determine the extent to which the quasi-experimental study design is used to evaluate infection control and antibiotic resistance. We evaluated studies on the basis of the following criteria: type of quasi-experimental study design used, justification of the use of the design, use of correct nomenclature to describe the design, and recognition of potential limitations of the design. A total of 73 articles featured a quasi-experimental study design. Twelve (16%) were associated with a quasi-exper- imental design involving a control group. Three (4%) provided justification for the use of the quasi-experimental study design. Sixteen (22%) used correct nomenclature to describe the study. Seventeen (23%) mentioned at least 1 of the potential limitations of the use of a quasi-experimental study design.
    [Show full text]
  • Meta-Analysis of Observational Studies in Epidemiology (MOOSE)
    CONSENSUS STATEMENT Meta-analysis of Observational Studies in Epidemiology A Proposal for Reporting Donna F. Stroup, PhD, MSc Objective Because of the pressure for timely, informed decisions in public health and Jesse A. Berlin, ScD clinical practice and the explosion of information in the scientific literature, research Sally C. Morton, PhD results must be synthesized. Meta-analyses are increasingly used to address this prob- lem, and they often evaluate observational studies. A workshop was held in Atlanta, Ingram Olkin, PhD Ga, in April 1997, to examine the reporting of meta-analyses of observational studies G. David Williamson, PhD and to make recommendations to aid authors, reviewers, editors, and readers. Drummond Rennie, MD Participants Twenty-seven participants were selected by a steering committee, based on expertise in clinical practice, trials, statistics, epidemiology, social sciences, and biomedi- David Moher, MSc cal editing. Deliberations of the workshop were open to other interested scientists. Fund- Betsy J. Becker, PhD ing for this activity was provided by the Centers for Disease Control and Prevention. Theresa Ann Sipe, PhD Evidence We conducted a systematic review of the published literature on the con- duct and reporting of meta-analyses in observational studies using MEDLINE, Educa- Stephen B. Thacker, MD, MSc tional Research Information Center (ERIC), PsycLIT, and the Current Index to Statistics. for the Meta-analysis Of We also examined reference lists of the 32 studies retrieved and contacted experts in Observational Studies in the field. Participants were assigned to small-group discussions on the subjects of bias, Epidemiology (MOOSE) Group searching and abstracting, heterogeneity, study categorization, and statistical methods.
    [Show full text]
  • Epidemiology and Statistics for the Ophthalmologist
    This book will give ophthalmologists a simple, clear presentation of epidemiologic and statistical techniques relevant to conducting, inter­ preting, and assimilating the commonest types of clinical research. Such information has become all the more important as clinical ophthalmic research has shifted from anecdotal reports and un­ critical presentations of patient data to carefully controlled and organized studies. The text is divided into two parts. The first part deals with epi­ demiologic concepts and their application and with the various types of studies (for example, prospective or longitudinal) and their organization (use of controls, randomness, sources of bias, choice of sample size, standardization and reproducibility). The second half of the text is devoted to the selection and use of the relevant sta­ tistical manipulations: determining sample size and testing the sta­ tistical significance of results. The text is illustrated with many examples covering topics such as blindness registry data, incidence of visual field loss with different levels of ocular hypertension, sensi­ tivity and specificity of tests for glaucoma, and sampling bias in studies of the safety of intraocular lenses. References and several helpful appendices are included. The Author Alfred Sommer received his M.D. in Ophthalmology from Harvard University Medical School, and his M.H. Sc. degree in Epidemiology from Johns Hopkins School of Hygiene and Public Health. At the Wilmer Institute, he is the Director of the International Center for Epidemiologic and Preventive Ophthalmology. He is the author of Field Guide to the Detection and Control of Xerophthalmia. Oxford University Press, N ew York Cover design by Joy Taylor ISBN O-19-502656-X Epidemiology and Statistics for the Ophthalmologist ALFRED SOMMER, M.D., M.R.Se.
    [Show full text]
  • COLLEGE of PUBLIC HEALTH CURRICULUM VITAE Robert B
    COLLEGE OF PUBLIC HEALTH CURRICULUM VITAE Robert B. Wallace February 27, 2017 I. EDUCATIONAL AND PROFESSIONAL HISTORY A. Education (least to most recent) (includes undergraduate, graduate, and postgraduate education) Institution Dates Field of Degree Degree Attended Study Obtained Date Northwestern University Medical Medicine B.S.M. 1964 School, Chicago, IL Northwestern University Medical Medicine M.D. 1967 School, Chicago, IL Cornell University Hospitals 1967-68 Intern Internal Medicine Cornell University Hospitals 1968-69 Resident Internal Medicine State University of New York at Epidemiology M.Sc. 1972 Buffalo, Buffalo, NY Certification/Licensure Board Date Certification American Board of Preventive Medicine 1974, Diplomate American Board of Preventive Medicine 1996, Fellow Licensure Iowa Medicine 1972 Perm. # 18838 Renewal Date 10/01/14 1 B. Professional and Academic Positions Dates Position Title of Service Location/Institution Instructor 1969-70 Emory University, School of Medicine, Dept. of Medicine Epidemic Intelligence Service 1969-72 Center for Disease Control Officer U.S. Public Health Office Instructor 1970-72 State University of New York at Buffalo, Dept. of Social and Preventive Medicine Assistant Professor 1972-75 Depts. of Preventive Medicine & Environmental Health, and Internal Medicine, College of Medicine, The University of Iowa Associate Professor 1975-79 Depts. of Preventive Medicine & Environmental Health, and Internal Medicine, College of Medicine, The University of Iowa Director, Epidemiology Section 1976-85 Depts
    [Show full text]
  • Rocreg — Receiver Operating Characteristic (ROC) Regression
    Title stata.com rocreg — Receiver operating characteristic (ROC) regression Description Quick start Menu Syntax Options Remarks and examples Stored results Methods and formulas Acknowledgments References Also see Description The rocreg command is used to perform receiver operating characteristic (ROC) analyses with rating and discrete classification data under the presence of covariates. The two variables refvar and classvar must be numeric. The reference variable indicates the true state of the observation—such as diseased and nondiseased or normal and abnormal—and must be coded as 0 and 1. The refvar coded as 0 can also be called the control population, while the refvar coded as 1 comprises the case population. The rating or outcome of the diagnostic test or test modality is recorded in classvar, which must be ordinal, with higher values indicating higher risk. rocreg can fit three models: a nonparametric model, a parametric probit model that uses the bootstrap for inference, and a parametric probit model fit using maximum likelihood. Quick start Nonparametric estimation with bootstrap resampling Area under the ROC curve for test classifier v1 and true state true using seed 20547 rocreg true v1, bseed(20547) Add v2 as an additional classifier rocreg true v1 v2, bseed(20547) As above, but estimate ROC value for a false-positive rate of 0.7 rocreg true v1 v2, bseed(20547) roc(.7) Covariate stratification of controls by categorical variable a using seed 121819 rocreg true v1 v2, bseed(121819) ctrlcov(a) Linear control covariate adjustment with
    [Show full text]
  • George W. Comstock Center for Public Health Research and Prevention
    George W. Comstock Center for Public Health Research and Prevention 1100 Dual Highway, Hagerstown, MD For more information about the Comstock Center, visit our website: http://www.jhsph.edu/comstockcenter The George W. Comstock Center for Public Health Research and Prevention 1100 Dual Highway, Suite A Hagerstown, MD 21740 Phone: 301.791.1847, 301.733.8860, 301.797.3589 Fax: 301.791.3541 Center Director: Josef Coresh, MD PhD [email protected] Center Operations Director: Pat Crowley, M.S. [email protected] Health Monitoring Unit Supervisor: Judy Hoffman-Bolton [email protected] Message from the Director The George W. Comstock Center for Public Health Research and Prevention connects scientists, students, and staff at Johns Hopkins University with participants from Washington County, Maryland, to improve the evidence base for prevention efforts. The science aims to leave a lasting legacy of data and knowledge which will improve health and prevent disease in Washington County, nationally and internationally. We benefit from nearly a century of innovation and collaboration between scientists and the community. New studies benefit from the data, experience and wisdom accumulated in previous studies. The research facility we opened in 2011 brings together our original unit, based at the Health Department since 1962, with the downtown Hagerstown unit, which has operated since 1986. Having both units under one roof facilitates sharing expertise across the full range of research activities, from large mail surveys and specimen bank studies to in‐depth clinical research studies. Our strengths in clinic‐based studies of heart disease, diabetes, aging, cognition and sleep disorders will enhance our leading studies of cancer etiology as they requiremorein‐depth molecular characterization.
    [Show full text]